Temsirolimus, a novel inhibitor of the mammalian target of rapamycin (mTOR), improves overall survival and progression-free survival in patients with advanced renal cell carcinoma (RCC) compared with interferon (Hudes et al, 2007). The gene discussed is MTOR; the disease is renal cell carcinoma.